{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T05:56:25Z","timestamp":1781762185257,"version":"3.54.5"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Unresectable hepatocellular carcinoma (uHCC) patients with portal vein tumor thrombus (PVTT) have a substandard prognosis. This study elucidated whether conversion therapy can alleviate unresectable tumors and increase the rate of salvage hepatectomy, as well as identify predictors of better prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study analyzed 159 patients with uHCC and PVTT who underwent conversion therapy, predominantly combining systemic treatments with transarterial chemoembolization (TACE). Primary endpoints were progression-free survival (PFS) and overall survival (OS). Secondary endpoints included tumor response, surgical conversion rate, and outcomes in the surgical cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The data showed that the objective response rates (ORR) for the entire cohort (n = 159) were 42.1%, while the disease control rate was 62.3%. The median PFS and OS were respectively determined to be 9.6 and 17.7 months. Moreover, 40 patients (25.2%) were successfully converted and underwent salvage hepatectomy. In addition, the surgical subgroup indicated a markedly improved median recurrence-free survival (RFS; 10.1 months) and OS (30 months). Multivariate analysis revealed that salvage hepatectomy was an independent protective factor for both PFS (95% CI: 0.341 - 0.845, HR\u00a0=\u00a00.537,\n                      <jats:italic>p = 0.007<\/jats:italic>\n                      ) and OS (95% CI: 0.273 - 0.777, HR\u00a0=\u00a00.460,\n                      <jats:italic>p = 0.004<\/jats:italic>\n                      ). Whereas for poorer outcomes, an independent predictor was advanced Cheng\u2019s PVTT classification (OS: HR\u00a0=\u00a01.719,\n                      <jats:italic>p &amp;lt; 0.001<\/jats:italic>\n                      ). Multivariate logistic regression showed that a single tumor (OR\u00a0=\u00a00.402,\n                      <jats:italic>p = 0.024<\/jats:italic>\n                      ) and a lower baseline aspartate aminotransferase level (OR\u00a0=\u00a00.453,\n                      <jats:italic>p = 0.038<\/jats:italic>\n                      ) were independent predictors of successful conversion to surgery. Of the 40 surgical patients, 11 (27.5%) attained a pathologic complete response (pCR). Although patients with pCR showed a numerically favorable survival trend (median RFS of 14.0 months vs. 4.5 months for major pathological response), this difference did not reach statistical significance. Adverse events associated with treatment were manageable, with grade \u2265 3 adverse events observed in 19.5% of patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This retrospective study evaluated the combined effect of systemic therapy and TACE as an efficient conversion therapy for uHCC patients with PVTT. The findings revealed a substantial response rate, facilitating curative-intent surgery in a substantial percentage of patients. Salvage hepatectomy was associated with improved survival in selected patients who responded to conversion therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1749090","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T05:36:25Z","timestamp":1781760985000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of combined modality conversion therapy for HCC with portal vein tumor thrombus: a retrospective cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Jian","family":"Huang","sequence":"first","affiliation":[{"name":"The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Chen","family":"Liu","sequence":"additional","affiliation":[{"name":"The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Eastern Hepatobiliary Surgery Hospital, Naval Medical University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Dong","sequence":"additional","affiliation":[{"name":"The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Xian","family":"Yuan","sequence":"additional","affiliation":[{"name":"The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-Ming","family":"Gu","sequence":"additional","affiliation":[{"name":"The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei-Ge","family":"Jiang","sequence":"additional","affiliation":[{"name":"The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze-Ya","family":"Pan","sequence":"additional","affiliation":[{"name":"The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199808000-00014","article-title":"Natural history of untreated primary hepatocellular carcinoma: A retrospective study of 157 patients","volume":"21","author":"Pawarode","year":"1998","journal-title":"Am J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"Bclc strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (Ibi305) versus sorafenib in unresectable hepatocellular carcinoma (Orient-32): A randomised, open-label, phase 2\u20133 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1466113","article-title":"Efficacy and safety of transarterial chemoembolization plus lenvatinib combined with Pd-1 inhibitors versus transarterial chemoembolization plus lenvatinib for unresectable hepatocellular carcinoma: A meta-analysis","volume":"15","author":"Chen","year":"2024","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1586914","article-title":"Efficacy and safety of lenvatinib plus transarterial chemoembolization with or without programmed death-1 inhibitors in the treatment of intermediate or advanced hepatocellular carcinoma: A systematic review and meta-analysis","volume":"16","author":"Lei","year":"2025","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: A new evidence-based approach-the Albi grade","volume":"33","author":"Johnson","year":"2015","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn.2019.10.07","article-title":"A new classification for hepatocellular carcinoma with hepatic vein tumor thrombus","volume":"9","author":"Chen","year":"2020","journal-title":"Hepatobiliary Surg Nutr"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8386","article-title":"Multidisciplinary management of hepatocellular carcinoma with portal vein tumor thrombus - Eastern Hepatobiliary Surgical Hospital consensus statement","volume":"7","author":"Cheng","year":"2016","journal-title":"Oncotarget"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0344-0338(11)80700-4","article-title":"The pathologist and the residual tumor (R) classification","volume":"190","author":"Hermanek","year":"1994","journal-title":"Pathol Res Pract"},{"key":"B13","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1159\/000509424","article-title":"Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 edition)","volume":"9","author":"Zhou","year":"2020","journal-title":"Liver Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn-22-373","article-title":"Hepatocellular carcinoma with portal invasion, still a place for liver surgery in the era of immunotherapy","volume":"11","author":"Giudicelli","year":"2022","journal-title":"Hepatobiliary Surg Nutr"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn-20-854","article-title":"Neoadjuvant radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: A systematic review","volume":"11","author":"Wei","year":"2022","journal-title":"Hepatobiliary Surg Nutr"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S332420","article-title":"Lenvatinib combined with anti-Pd-1 antibodies plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A multicenter retrospective study","volume":"8","author":"Wu","year":"2021","journal-title":"J Hepatocell Carcinoma"},{"key":"B17","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/hep.31022","article-title":"Prediction of survival among patients receiving transarterial chemoembolization for hepatocellular carcinoma: A response-based approach","volume":"72","author":"Han","year":"2020","journal-title":"Hepatology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1198562","article-title":"Efficacy and safety of lenvatinib-based combination therapies for patients with unresectable hepatocellular carcinoma: A single center retrospective study","volume":"14","author":"Huang","year":"2023","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","article-title":"Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma","volume":"18","author":"Llovet","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ctrv.2018.08.006","article-title":"Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy","volume":"74","author":"Chang","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1159\/000514313","article-title":"Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and anti-Pd-1 antibody combinations","volume":"10","author":"Zhu","year":"2021","journal-title":"Liver Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-12530-z","article-title":"Hepatectomy after conversion therapy using tyrosine kinase inhibitors plus anti-Pd-1 antibody therapy for patients with unresectable hepatocellular carcinoma","volume":"30","author":"Zhu","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-023-10561-6","article-title":"Perioperative safety, oncologic outcome, and risk factors of salvage liver resection for initially unresectable hepatocellular carcinoma converted by transarterial chemoembolization plus tyrosine kinase inhibitor and anti-Pd-1 antibody: A retrospective multicenter study of 83 patients","volume":"17","author":"Lin","year":"2023","journal-title":"Hepatol Int"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-0142(19970215)79:4<688::aid-cncr5>3.0.co;2-a","article-title":"Relationship between the recurrence of hepatocellular carcinoma (Hcc) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virus-associated cirrhosis and Hcc","volume":"79","author":"Tarao","year":"1997","journal-title":"Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-012-9357-4","article-title":"Up-regulation of Dbpa Mrna in hepatocellular carcinoma associated with metabolic syndrome","volume":"7","author":"Obulhasim","year":"2013","journal-title":"Hepatol Int"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: The Ctneobc pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318247504a","article-title":"Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy","volume":"7","author":"Pataer","year":"2012","journal-title":"J Thorac Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26120","article-title":"Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies","volume":"57","author":"Duffy","year":"2013","journal-title":"Hepatology"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2019.05.004","article-title":"Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma","volume":"77","author":"Rimassa","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"B30","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1080\/15569527.2025.2552715","article-title":"Acute cutaneous adverse drug reactions in hepatocellular carcinoma patients undergoing combined targeted and immunotherapy: Unraveling the impact of dosage and interval","volume":"44","author":"Li","year":"2025","journal-title":"Cutan Ocul Toxicol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1749090\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T05:36:26Z","timestamp":1781760986000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1749090\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":30,"alternative-id":["10.3389\/fimmu.2026.1749090"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1749090","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"article-number":"1749090"}}